Tag Archives: IFM

IFM’s Hat Trick and Reflections On Option-To-Buy M&A
March 13, 2024

Today IFM Therapeutics announced the acquisition of IFM Due, one of its subsidiaries, by Novartis. Back in Sept 2019, IFM granted Novartis the right to acquire IFM Due as part of an “option to buy” collaboration around cGAS-STING antagonists for

Leave a comment

Sharing An Innate Desire To Address Inflammation: Novartis and IFM Team Up
April 1, 2019

Today Novartis announced the acquisition of IFM Therapeutics’ portfolio of NLRP3 antagonists, via the purchase of IFM Tre, a subsidiary of IFM (here, here). These immunomodulatory medicines target the inflammasome, a key innate immune node whose pathologic chronic activation is associated with

Leave a comment